Abstract 4CPS-038 Table 1
Number of patients (%) before treatment with DupilumabNumber of patients (%) after treatment with Dupilumab
SCORAD indexmild disease score (SCORAD<25)0 (0%)2 (33%)
moderate disease score (25<SCORAD<50)1 (17%)3 (50%)
severe disease score (SCORAD>50)5 (83%)1 (17%)
DLQI questionnaire0–1 (no effect at all on patient’s life)1 (17%)3 (50%)
2–5 (small effect on patient’s life)0 (0%)1 (17%)
6–10 (moderate effect on patient’s life)0 (0%)1 (17%)
11–20 (very large effect on patient’s life)1 (17%)1 (17%)
21–30 (extremely large effect on patient’s life)4 (66%)0 (0%)
HADS questionnairedepression (D)
0–7 (normal)3 (50%)5 (83%)
8–10 (borderline abnormal)0 (0%)1 (17%)
11–21 (abnormal)3 (50%)0 (0%)
anxiety (A)
0–7 (normal)1 (17%)3 (50%)
8–10 (borderline abnormal)1 (17%)2 (33%)
11–21 (abnormal)4 (66%)1 (17%)